Tyrosine-protein kinase fusion nucleophosmin–anaplastic lymphoma kinase (NPM-ALK)

Tyrosine-protein kinase fusion nucleophosmin–anaplastic lymphoma kinase (NPM-ALK) is an oncogenic fusion protein formed by a chromosomal translocation [t(2;5)(p23;q35)] that fuses the N-terminal domain of nucleophosmin (NPM) to the kinase domain of anaplastic lymphoma kinase (ALK). This fusion results in constitutive activation of the ALK tyrosine kinase, driving uncontrolled cell proliferation, anti-apoptotic signaling, and malignant transformation, most notably in anaplastic large cell lymphoma (ALCL)[2][3][4]. NPM-ALK activates several signaling pathways, including PI3K/AKT and JAK/STAT3, and induces expression of regulatory proteins like IL-10 and FoxP3 that contribute to immune evasion and cancer progression[1][2]. NPM-ALK is a clinically validated therapeutic target in ALCL, and ALK tyrosine kinase inhibitors such as crizotinib and alectinib are approved therapies for ALK-positive cancers[3][4]. Detection of NPM-ALK by IHC or molecular assays serves as a diagnostic and predictive biomarker. Therapeutic resistance and off-target toxicities are important challenges in clinical management.

Other names

Nucleophosmin–anaplastic lymphoma kinaseNPM–ALK fusion proteinNPM/ALKNPM-ALK kinaseAnaplastic lymphoma kinase fusionALK-NPM

Inhibition of kinase activity by direct binding to the ALK kinase domain. Disruption of constitutive downstream oncogenic signaling (PI3K/AKT, JAK/STAT3 pathways, etc.). Induction of apoptosis in ALK fusion–positive tumor cells.